Quick Answer
RELMADA THERAPEUTICS, INC. reported Research And Development Expense of $26.88 million for the year ending 2025.
- RELMADA THERAPEUTICS, INC. showed a decrease of -41.8% in Research And Development Expense from 2024 to 2025.
- This data is from RELMADA THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), RELMADA THERAPEUTICS, INC.'s Research And Development Expense has grown by 412.1%.
- Historical annual values: Fiscal year 2025: $26.88 million | Fiscal year 2024: $46.18 million | Fiscal year 2023: $54.81 million | Fiscal year 2022: $113.32 million | Fiscal year 2021: $90.62 million | Fiscal year 2020: $35.97 million | Fiscal year 2019: $7.86 million | Fiscal year 2019: $7.02 million | Fiscal year 2018: $2.94 million | Fiscal year 2017: $1.29 million | Fiscal year 2016: $6.21 million | Fiscal year 2015: $7.87 million | Fiscal year 2013: $5.25 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: